Trials / Completed
CompletedNCT01514448
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Everolimus (RAD001) | Everolimus was used as commercially available formulated tablets of 10 mg strength |
Timeline
- Start date
- 2012-05-21
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2012-01-23
- Last updated
- 2017-07-19
- Results posted
- 2017-07-19
Locations
13 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01514448. Inclusion in this directory is not an endorsement.